| 4/15/2008 |
Section 409A Valuations and Stock Option Grants for Start-up Technology and Life Science Companies |
 |
| Federal, and at least one state's, tax laws make it especially important for companies granting stock options as compensation to set the exercise price of the underlying shares at or above the price that can be shown by a reasonable valuation method to be fair market value (FMV) at the time of grant. more |
|
 |
| 3/19/2008 |
2007 Silicon Valley Life Science VC Survey |
|
| The results of our fourth annual San Francisco Bay Area Life Science Venture Capital Valuation Survey
show a continuation of the positive trend in the life science venture environment. more |
|
|
| 8/31/2007 |
Perspective: Patents, post-MedImmune |
|
| Earlier this year, the Supreme Court shook the foundations of patent licensing and technology transfer, altering the balance of power between patent holders and their licensees and creating profound implications for the life-sciences industry. more |
|
|
| 7/30/2007 |
Litigation Alert: Integra LifeSciences I, Ltd. v. Merck KGaA - Applying the Supreme Court's Broad Interpretation of the FDA Exemption for Patent Infringement |
|
| On July 27, the Federal Circuit in Integra LifeSciences v. Merck ruled on the Supreme Court's broad interpretation of the patent infringement exemption set forth in 35 U.S.C. § 271(e)(1), for "uses reasonably related to the development and submission of information" to the Food and Drug Administration (FDA). more |
|
|
| 1/10/2007 |
Litigation Alert - Supreme Court Knocks Down Federal Circuit Rule and Allows Licensees to Challenge a Licensed Patent |
|
| Yesterday, the Supreme Court ruled in MedImmune v. Genentech that a patent licensee does not need to breach its license agreement before seeking a declaratory judgment in federal court that the underlying patent is invalid, unenforceable, or not infringed. more |
|
|
| 9/21/2006 |
2006 Trends in Life Sciences Partnering, Collaborations and Strategic Alliances |
|
| Rising drug development costs, uncertain capital markets, and increased regulatory hurdles continue to drive life sciences company strategies during 2006. more |
|
|
| 4/5/2006 |
Putting the "Co" in Development and Promotion: The New Biotech-Pharma Collaborations |
|
| A number of strategic reasons exist for partnering among life sciences companies. more |
|
|
| 3/28/2006 |
2005 Trends in Life Sciences Partnering and Collaborations |
|
| Ten years ago, when a biotech company needed to raise capital, the avenue most frequently sought was the capital markets. Today, rising
drug development costs can approach $1 billion, making a biotech's need for capital more intense than ever. more |
|
|
| 3/7/2006 |
Life Sciences Companies Face Special Disclosure Challenges |
|
| Life sciences companies face difficult disclosure issues because they operate in a particularly complex and financially sensitive regulatory environment. more |
|
|
| 1/3/2006 |
University Licensing: An Introduction to Licensing Technology from Universities |
|
| What do Yamaha synthesizers, gene splicing and DSL have in common? They are all based on technology licensed from universities. As these examples show, universities often develop and license new cutting edge technologies. more |
|
|
| 11/11/2005 |
Follow-on Biological Products—Legal Issues |
|
| Many biologics, including blockbusters like Epogen/Procrit, are nearing patent expiration, and generics manufacturers, including Sicor (acquired by Teva), Barr Laboratories, and Ivax Corporation, are hoping to market generic biologics. more |
|
|
| 11/3/2005 |
Authorized Generics: Antitrust Issues and the Hatch-Waxman Act |
|
| An authorized generic (AG) is a pharmaceutical product that was originally marketed and sold by a brand company, but is relabeled and marketed under a generic product name. more |
|
|
